The global insulin delivery pens market size is predicted to increase from USD 25,578 million in 2025 and is anticipated to ...

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out ...

Novo Nordisk clarifies Human Mixtard penfill to be replaced with injectables: Our Bureau, Bengaluru Wednesday, April 23, 2025, 13:30 Hrs [IST] Denmark-based global pharma major, N ...

Thirty-seven-year-old Nupur Lalvani, who has been living with Type 1 diabetes since the age of eight, was dependent on ...

ISLAMABAD, Apr 23 (China Economic Net) - The insulin glargine cartridge by Gan & Lee Pharmaceuticals just obtained the first biosimilar approval from the Drug Regulatory Authority of Pakistan (DRAP), ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...

Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand.

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global ...

The Global Insulin Pump Market achieved a valuation of $5.90 Billion in 2024 and is anticipated to exceed $14.49 Billion by 2035, reflecting a compounded annual growth rate (CAGR) of 8.55% during the ...